Techno Vax
Biotechnology, 6 Westchester PLZ, Elmsford, New York, 10523, United States, 1-10 Employees
Phone Number: +14*********
Who is TECHNOVAX
TechnoVax is a privately held near-clinical-stage biotechnology company based in Tarrytown, NY specializing in viral vaccine development. Our mission is to create and advance towards the ...
Read More
- Headquarters: 6 Westchester PLZ, Elmsford, New York, 10523, United States
- Date Founded: 2003
- Employees: 1-10
- Revenue: $1 Million to $5 Million
- Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 5046 | NAICS Code: 423450 | Show More
TechnoVax Org Chart and Mapping
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding TechnoVax
Answer: TechnoVax's headquarters are located at 6 Westchester PLZ, Elmsford, New York, 10523, United States
Answer: TechnoVax's phone number is +14*********
Answer: TechnoVax's official website is https://technovax.com
Answer: TechnoVax's revenue is $1 Million to $5 Million
Answer: TechnoVax's SIC: 5046
Answer: TechnoVax's NAICS: 423450
Answer: TechnoVax has 1-10 employees
Answer: TechnoVax is in Biotechnology
Answer: TechnoVax contact info: Phone number: +14********* Website: https://technovax.com
Answer: TechnoVax is a privately held near-clinical-stage biotechnology company based in Tarrytown, NY specializing in viral vaccine development. Our mission is to create and advance towards the market safe, unique and novel vaccine technologies with no current alternatives that will revolutionize the way vaccines are developed, distributed and administered. TechnoVax has developed a next-generation technology-platform based on Virus-Like Particles (VLP) that greatly enhances and facilitates the development and production of a limitless range of vaccines targeting the prevention of respiratory diseases as well as hemorrhagic fevers, immunodeficiency and cancers. The industry strongly believes that VLP based vaccines is the technology of the future! Our vaccines pipeline has been rapidly approaching the clinical phases with 3 main candidates: - A Universal flu vaccine that will eliminate the need for annual flu vaccination and will protect faster and better against future pandemic strains; - An Inhaled Powder flu vaccine that eliminates the need for cold chain storage and distribution and could be self-administered: a greatly needed solution for the developing world; - An RSV vaccine to protect against one of the leading causes of infant and elderly hospitalizations and often results in fatalities with the elderly. We have received over $5.0 million in non-dilutive funding. We are actively pursuing strategic partnerships and are seeking funding to start human testing.
Answer:
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Sign in to CIENCE GO Data to uncover contact details
Free credits every month